Results by Type
News Results 1-10 of 55
Xanodyne Pharmaceuticals, Inc. Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
News | www.biospace.com | Aug 5, 2008
NEWPORT, Ky., Aug. 5 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. announced today positive top line results in two pivotal Phase 3 clinical trials of its proprietary investigational product, a modified-release (MR) formulation of tranexamic acid for the treatment of women with menorrhagia, or
http://www.biospace.com/news_story.aspx?StoryID=105706&full=1
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
Press Release | www.prnewswire.com | Aug 5, 2008
Flexter, President and Chief Executive Officer of Xanodyne. In addition to these two recently completed Phase 3 clinical trials, which evaluated the efficacy and safety of tranexamic acid MR, two additional open-label safety trials are ongoing.
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/08-05-2008/0004861691&EDATE=
ORIGINAL ARTICLE: A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery
News | content.nejm.org | May 28, 2008
Original Article from The New England Journal of Medicine -- A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery
http://content.nejm.org/cgi/content/short/358/22/2319?rss=1&query=current
Company and People Notes: Bayer to Remove Trasylol, Cambrex Appoints Steven M. Klosk president and CEO, More
News | pharmtech.findpharma.com | May 20, 2008
Also, Pfizer to close Indiana "Exubera" facility, executive appointments at Patheon, more...
Blood Loss Drug Again Found to Increase Death Rates in Surgery Patients
News | www10.nytimes.com | May 15, 2008
Experts say the anti-bleeding drug, now off the market, likely will never return.
Aprotinin (Trasylol) Down But Not Totally Out
News | www.medpagetoday.com | May 15, 2008
ROCKVILLE, Md. -- The hemostasis drug aprotinin (Trasylol) will remain available to U.S. physicians under an investigational protocol, at least until the FDA sorts out the causes of excess deaths seen
http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/9467
Bayer pulls Trasylol supplies after study
News | uk.reuters.com | May 15, 2008
By Gene Emery BOSTON (Reuters) - Bayer AG is removing remaining supplies of its heart-surgery drug Trasylol from the U.S. market after a long-awaited study found it raised the risk of death compared
http://uk.reuters.com/article/healthNews/idUKN1449840720080515?feedType=RSS&feedName=healthNews
Bayer pulls Trasylol supplies after study (Reuters)
News | biz.yahoo.com | May 15, 2008
Bayer pulls Trasylol supplies after study. - BOSTON (Reuters) - Bayer AG (XETRA:BAYG.
Drug aprotinin boosts risk of death: study
News | uk.news.yahoo.com | May 14, 2008
Aprotinin, a drug often used to prevent blood loss during heart surgery, boosts the risk of death by 50 percent, a major clinical study done in Canada and published in the United
http://uk.news.yahoo.com/afp/20080514/thl-us-health-medicine-0b0437e.html
LegalView Reports Mine Safety and Health Administration's Reduction of Asbestos Permissible Exposure Allowances by Nearly 95 Percent
Press Release | www.prleap.com | Mar 12, 2008
LegalView alerted mesothelioma blog readers of lowered asbestos exposure allowances, which were amended by the Mine Safety and Health Administration recently. The new limits were reduced by 95 percent of original limits and could increase the number of mesothelioma cancer reports among mine workers.
Or copy the embed script code below and paste it on your website:
Embed code:
>
